Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
246
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Phase I study of AR-42 and decitabine in acute myeloid leukemia

Sophia G. LivaDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; View further author information
,
Christopher C. CossDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; View further author information
,
Jiang WangCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; View further author information
,
William BlumDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; View further author information
,
Rebecca KlisovicDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; View further author information
,
Bhavana BhatnagarDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Katherine WalshDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Susan GeyerMayo Clinic, Rochester, MN, USA; View further author information
,
Qiuhong ZhaoDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Ramiro GarzonDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Guido MarcucciDepartment of Hematologic Malignancies Translational Science, City of Hope, Duarte, CA, USAView further author information
,
Mitch A. PhelpsDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; View further author information
&
Alison R. WalkerDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]
View further author information
 show all
Pages 1484-1492 | Received 04 Nov 2019, Accepted 16 Jan 2020, Published online: 08 Feb 2020

References

  • Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
  • Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016;127(1):42–52.
  • O’Donnell MR, et al. Acute myeloid leukemia, Version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(7):926–957.
  • Lubbert M, Kuendgen A. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges. Cancer. 2015;121(4):498–501.
  • Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011;25(2):226–235.
  • Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12(15):4628–4635.
  • Lu Q, Yang Y-T, Chen C-S, et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004;47(2):467–474.
  • Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. JCO. 2007;25(21):3109–3115.
  • Mims A, Walker AR, Huang X, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013;27(4):871–878.
  • Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411–6418.
  • Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010; 107(16) :7473–7478.
  • Hunsberger S, Rubinstein LV, Dancey J, et al. Dose escalation trial designs based on a molecularly targeted endpoint. Statist Med. 2005; 24(14) :2171–2181.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JCO. 2003;21(24):4642–4649.
  • Sborov DW, Canella A, Hade EM, et al. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma. 2017;58(10):2310–2318.
  • Moisey LL, Mourtzakis M, Kozar RA, et al. Existing equations to estimate lean body mass are not accurate in the critically ill: results of a multicenter observational study. Clin Nutr. 2017;36(6):1701–1706.
  • Kim YH, Choi HY, Noh Y-H, et al. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study. Drug Des Devel Ther. 2015;9:2911–2918.
  • Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247–1252.
  • Wolf JL, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia Lymphoma. 2012;53(9):1820–1823.
  • Shah MH. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997–4003.
  • Moreau P, Facon T, Touzeau C, et al. Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. Leuk Lymphoma. 2016;57(7):1546–1559.
  • Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006.
  • Hopkins JJ, Sawyer MB. A review of body composition and pharmacokinetics in oncology. Expert Rev Clin Pharmacol. 2017;10(9):947–956.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.